Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country

Journal of the Pakistan Medical Association

Volumn 57, Issue 10, 2007, Pages 484-487

  Siddiqui, Shahla ^a   Hussein, Kashif ^c   Manasia, Roshan ^c   Samad, Aijaz ^a   Salahuddin, Nawal ^b   Zafar, Afia ^a   Hoda, M Qamarul ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN TAZOBACTAM COMBINATION PRODUCT; PIPERACILLIN-TAZOBACTAM COMBINATION PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; CONSULTATION; DEVELOPING COUNTRY; DRUG COST; INTENSIVE CARE UNIT; VENTILATOR ASSOCIATED PNEUMONIA; ANTIBIOTIC RESISTANCE; CLASSIFICATION; DRUG USE; HOSPITAL INFORMATION SYSTEM; HUMAN; POLICY; PRESCRIPTION; PROGRAM DEVELOPMENT; STANDARD;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DEVELOPING COUNTRIES; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION REVIEW; HUMANS; IMIPENEM; INTENSIVE CARE UNITS; MEDICAL ORDER ENTRY SYSTEMS; ORGANIZATIONAL POLICY; PENICILLANIC ACID; PIPERACILLIN; POLYMYXIN B; PRESCRIPTIONS, DRUG; PROGRAM DEVELOPMENT; VANCOMYCIN;

EID: 38449114624     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bassetti M, Di Biagio A, Rebesco B, Amalfitano ME, Topal J, Bassetti D. The effect of formulary restriction in the use of antibiotics in an Italian hospital. Eur J Clin Pharmacol 2001; 57:529-34.
2. Keuleyan E, Gould M. Key issues in developing antibiotic policies: from an institutional level to Europe-wide. European Study Group on Antibiotic Policy (ESGAP), Subgroup III. Clin Microbiol Infect 2001; 7 (Suppl 6):16-21.
3. Mayer KH. The epidemiology of antibiotic resistance in hospitals. J Antimicrob Chemother 1986; 18 (Suppl C):223-33.
4. Vlahovic-Palcevski V, Morovic M, Palcevski G. Antibiotic utilization at the university hospital after introducing an antibiotic policy. Eur J Clin Pharmacol 2000; 56:97-101.
5. Sirinavin S, Suvanakoot P, Sathapatayavongs B, Malatham K. Effect of antibiotic order form guiding rational use of expensive drugs on cost containment. Southeast Asian J Trop Med Public Health 1998, 29:636-42.
6. Schmid A, Pugin J, Chevrolet JC, Marsch S, Ludwig S, Stocker R et al. Burden of illness imposed by severe sepsis in Switzerland. Swiss Med Wkly 2004, 134:97-102.
7. Moerer O, Burchardi H. The cost of sepsis. Anaesthesist 2006; 55 (Suppl 1): 36-42.
8. Theaker C, Ormond-Wałshe S, Azadian B, Soni N. MRSA in the critically ill. J Hosp Infect 2001; 48:98-102.
9. Yap FH, Gomersall CD, Fung KS, Ho PL, Ho OM, Lam PK et al. Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. Clin Infect Dis 2004; 39:511-16.
10. Clements, A. C.Tong, E. N.Morton, A. P.Whitby. Risk stratification for surgical site infections in Australia: evaluation of the US National Nosocomial Infection Surveillance risk index. J Hosp Infect, 2007; 1991; 18(Suppl A):4-31.
11. Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA, Bush K. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime- hydrolyzing beta-lactamases in a single isolate. Antimicrob Agents Chemother 1994; 38:761-6.
12. DeVito JM, John JF, Jr. Effect of formulary restriction of cefotaxime usage. Arch Intern Med 1985; 145:1053-6.
13. Dunagan WC, Medoff G. Formulary control of antimicrobial usage. What price freedom? Diagn Microbiol Infect Dis 1993; 16:265-74.
14. Apisarnthanarak A, Danchaivijitr S, Khawcharoenporn T, Limsrivilai J, Warachan B, Bailey TC et al. Effectiveness of education and an antibiotic-control program in a tertiary care hospital in Thailand. Clin Infect Dis 2006; 42:768-75.
15. Muller A, Monnet DL, Talon D, Henon T, Bertrand X. Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital. Br J Clin Pharmacol 2006; 61:585-91.
16. Raveh D, Muallem-Zilcha E, Greenberg A, Wiener-Well Y, Schlesinger Y, Yinnon AM. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. Qjm 2006; 99: 397-406.
17. Schwartzberg E, Rubinovich S, Hassin D, Haspel J, Ben-Moshe A, Oren M et al. Developing und implementing a model for changing physicians' prescribing habits - the role of clinical pharmacy in leading the change. J Clin Pharm Ther 2006; 31:179-85.
18. Stephan F, Sax H, Wachsmuth M, Hoffmeyer P, Clergue F, Pittet D. Reduction of urinary tract infection and antibiotic use after surgery: a controlled, prospective, before-after intervention study. Clin Infect Dis 2006; 42:1544-51.
19. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. Hospital consumption of antibiotics in 15 European countries: results of the ESAC
20. Retrospective Data Collection (1997-2002). J Antimicrob Chemother 2006; 58:159-67.
21. Sandiumenge A, Diaz E, Rodriguez A, Vidaur L, Canadell L, Olona M et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006; 56: 5-31.
22. Patel V, Vaidya R, Naik D, Borker P: Irrational drug use in India: a prescription survey from Goa. J Postgrad Med 2005; 51:9-12.